Bacterial 30S ribosomal subunit and 50S ribosomal subunit (30S and 50S ribosomal subunits (bacterial))

The **bacterial 30S ribosomal subunit** and **50S ribosomal subunit** are the two main parts of the prokaryotic (typically *Escherichia coli* model) ribosome, together forming the 70S ribosome—the central molecular machine for protein synthesis in bacteria. The 30S subunit is responsible for decoding messenger RNA (mRNA) and ensuring correct transfer RNA (tRNA) selection, while the 50S subunit catalyzes peptide bond formation and orchestrates the elongation of nascent peptides through its peptidyl transferase center and the protein exit tunnel. These subunits are therapeutically significant because a wide variety of antibiotics specifically bind to regions of the 30S or 50S subunit, interfering with essential stages of translation. Such inhibition leads to bacterial growth suppression or death and forms the basis of many front-line antibacterial therapies. Mechanisms of drug action include induction of mRNA misreading, inhibition of tRNA or translation factor association, blockade of peptide elongation/release, and impairment of subunit biogenesis. Antibacterial resistance frequently emerges through mutations in ribosomal RNA or proteins, altered drug binding sites, and protective enzymatic modifications, constituting an ongoing therapeutic challenge.

Other names

Bacterial ribosome small subunit (30S)Bacterial ribosome large subunit (50S)30S ribosome50S ribosomeBacterial 70S ribosome (when both subunits are assembled)Ribosomal subunits (bacterial)

Inhibition of decoding, leading to miscoding or premature translation termination (30S target, aminoglycosides). Blockade of tRNA binding to the A-site (30S and 50S targets). Inhibition of peptide bond formation (50S target, e.g., chloramphenicol). Blockade of the peptide exit tunnel, preventing nascent peptide elongation or release (50S target, e.g., macrolides, oxazolidinones). Interference with ribosomal biogenesis and subunit assembly, stalling protein synthesis at early stages. Inhibition of ribosome-mRNA/tRNA complex formation or function (both subunits).